Company intelligence / Profile preview
Alloplex Biotherapeutics
Woburn, Massachusetts, United Statesalloplexbio.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
In a Phase I trial, SUPLEXA showed promising results with no treatment-related serious adverse events. Among colorectal cancer patients, one had a complete response, one had a partial response, and one had stable disease, with responses lasting up to two years. Among 10 renal cell carcinoma patients, one had a partial response, six had stable disease, and three had progressive disease[6][9].
- Therapeutic areas
- Oncology
- Modalities
- Cellular therapyImmunotherapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Alloplex Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alloplex Biotherapeutics.